{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:49:09Z","timestamp":1794473349771,"version":"4.9.1"},"reference-count":25,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Patients with advanced chronic kidney disease (CKD) experience disproportionately high ischemic and bleeding risks following acute coronary syndrome (ACS), yet remain markedly underrepresented in randomized trials of antiplatelet therapy. Consequently, real-world data describing antiplatelet prescribing patterns and clinical outcomes in this population are limited. Objectives: To describe real-world antiplatelet use and 12-month clinical outcomes in patients with advanced CKD and end-stage renal disease (ESRD) following ACS. Methods: We conducted a single-center, retrospective cohort study including adults with advanced CKD (stage 4\u20135) or dialysis-dependent ESRD hospitalized with ACS and discharged on dual antiplatelet therapy. Baseline characteristics, revascularization strategies, and clinical outcomes were collected. Outcomes of interest included all-cause mortality, recurrent ischemic events (recurrent myocardial infarction, stroke or transient ischemic attack, or repeat revascularization), and bleeding events defined by Thrombolysis in Myocardial Infarction (TIMI) criteria over 12 months. All analyses were descriptive in nature. Results: A total of 222 patients were included; clopidogrel was prescribed in 96.0% of patients and ticagrelor in 4.0%. The cohort was elderly, highly comorbid, and predominantly dialysis-dependent. At 12 months, all-cause mortality occurred in approximately one-third of patients, recurrent ischemic events were frequent, and bleeding complications were common. Most bleeding events occurred in dialysis-dependent individuals. Outcomes among ticagrelor-treated patients are reported descriptively only due to the very small sample size. Conclusions: In this real-world cohort of patients with advanced CKD and ESRD following ACS, a substantial burden of mortality, recurrent ischemic events, and bleeding complications was observed, underscoring the narrow therapeutic window in this high-risk population. These findings are descriptive and hypothesis-generating, supporting the need for individualized antiplatelet strategies and prospective studies specifically enrolling patients with advanced CKD.<\/jats:p>","DOI":"10.3390\/jcm15083167","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:42:45Z","timestamp":1776771765000},"page":"3167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Antiplatelet Use and Clinical Outcomes in Patients with Advanced Chronic Kidney Disease Following Acute Coronary Syndrome: A Descriptive Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1549-0941","authenticated-orcid":false,"given":"Lama","family":"Alfehaid","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 3660, Riyadh 11481, Saudi Arabia"},{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, P.O. Box 3660, Riyadh 11481, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Alsubaie","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 3660, Riyadh 11481, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-1103","authenticated-orcid":false,"given":"Majed","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Care Department, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, P.O. Box 3660, Riyadh 11481, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4656-2478","authenticated-orcid":false,"given":"Mansour","family":"Alomran","sequence":"additional","affiliation":[{"name":"King Abdullah International Medical Research Center, P.O. Box 3660, Riyadh 11481, Saudi Arabia"},{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 3660, Riyadh 11481, Saudi Arabia"},{"name":"King Abdulaziz Cardiac Center, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh","family":"Alghadeer","sequence":"additional","affiliation":[{"name":"King Abdullah International Medical Research Center, P.O. Box 3660, Riyadh 11481, Saudi Arabia"},{"name":"College of Medicine, King Saud bin Abdulaziz University for Health Sciences, P.O. Box 3660, Riyadh 11481, Saudi Arabia"},{"name":"King Abdulaziz Cardiac Center, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e028492","DOI":"10.1161\/JAHA.122.028492","article-title":"Preferences of patients with chronic kidney disease for invasive versus conservative treatment of acute coronary syndrome","volume":"12","author":"Wilson","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.14797\/mdcj-9-3-169","article-title":"Redefining myocardial infarction: What is new in the ESC\/ACCF\/AHA\/WHF third universal definition of myocardial infarction?","volume":"9","author":"Jneid","year":"2013","journal-title":"Methodist Debakey Cardiovasc. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMra1216063","article-title":"Mechanisms of acute coronary syndromes and their implications for therapy","volume":"368","author":"Libby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/CIR.0000000000000183","article-title":"Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: A scientific statement from the American Heart Association","volume":"131","author":"Washam","year":"2015","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1161\/CIR.0000000000001397","article-title":"Correction to: 2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes","volume":"152","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/jama.2021.0716","article-title":"Oral antiplatelet therapy after acute coronary syndrome: A review","volume":"325","author":"Kamran","year":"2021","journal-title":"JAMA"},{"key":"ref_9","first-page":"443","article-title":"Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes","volume":"5","author":"Melloni","year":"2016","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","article-title":"Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function","volume":"122","author":"James","year":"2010","journal-title":"Circulation"},{"key":"ref_12","first-page":"400","article-title":"Efficacy and safety of ticagrelor for long-term secondary prevention according to renal function","volume":"37","author":"Magnani","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","article-title":"Ticagrelor in patients with stable coronary disease and diabetes","volume":"381","author":"Steg","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","article-title":"Platelet dysfunction in renal failure","volume":"30","author":"Boccardo","year":"2004","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gomchok, D., Ge, R.-L., and Wuren, T. (2023). Platelets in renal disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914724"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: A cohort study","volume":"16","author":"Ocak","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in myocardial infarction (TIMI) trial, phase I","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing PCI","volume":"40","author":"Urban","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/heartjnl-2017-312436","article-title":"Outcomes after myocardial infarction stratified by renal function","volume":"104","author":"Edfors","year":"2018","journal-title":"Heart"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Burlacu, A., Floria, M., Brinza, C., and Covic, A. (2023). Efficacy and safety of ticagrelor versus clopidogrel in dialysis patients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155011"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with chronic kidney disease","volume":"27","author":"Molnar","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: The SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical trial","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:26:05Z","timestamp":1776774365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/8\/3167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15083167"],"URL":"https:\/\/doi.org\/10.3390\/jcm15083167","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}